289 related articles for article (PubMed ID: 34497144)
1. Patients with mesenchymal tumours and high
Salvucci M; Crawford N; Stott K; Bullman S; Longley DB; Prehn JHM
Gut; 2022 Aug; 71(8):1600-1612. PubMed ID: 34497144
[TBL] [Abstract][Full Text] [Related]
2. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
[TBL] [Abstract][Full Text] [Related]
3. Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism.
Chen T; Li Q; Wu J; Wu Y; Peng W; Li H; Wang J; Tang X; Peng Y; Fu X
Cancer Immunol Immunother; 2018 Oct; 67(10):1635-1646. PubMed ID: 30121899
[TBL] [Abstract][Full Text] [Related]
4. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome.
Flanagan L; Schmid J; Ebert M; Soucek P; Kunicka T; Liska V; Bruha J; Neary P; Dezeeuw N; Tommasino M; Jenab M; Prehn JH; Hughes DJ
Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1381-90. PubMed ID: 24599709
[TBL] [Abstract][Full Text] [Related]
5. Fusobacterium nucleatum and Clinicopathologic Features of Colorectal Cancer: Results From the ColoCare Study.
Eisele Y; Mallea PM; Gigic B; Stephens WZ; Warby CA; Buhrke K; Lin T; Boehm J; Schrotz-King P; Hardikar S; Huang LC; Pickron TB; Scaife CL; Viskochil R; Koelsch T; Peoples AR; Pletneva MA; Bronner M; Schneider M; Ulrich AB; Swanson EA; Toriola AT; Shibata D; Li CI; Siegel EM; Figueiredo J; Janssen KP; Hauner H; Round J; Ulrich CM; Holowatyj AN; Ose J
Clin Colorectal Cancer; 2021 Sep; 20(3):e165-e172. PubMed ID: 33935016
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma.
Park HE; Kim JH; Cho NY; Lee HS; Kang GH
Virchows Arch; 2017 Sep; 471(3):329-336. PubMed ID: 28597080
[TBL] [Abstract][Full Text] [Related]
7. Increased Fusobacterium tumoural abundance affects immunogenicity in mucinous colorectal cancer and may be associated with improved clinical outcome.
Duggan WP; Salvucci M; Kisakol B; Lindner AU; Reynolds IS; Dussmann H; Fay J; O'Grady T; Longley DB; Ginty F; Mc Donough E; Slade DJ; Burke JP; Prehn JHM
J Mol Med (Berl); 2023 Jul; 101(7):829-841. PubMed ID: 37171483
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Immunological and Histopathological Features with Gene Expression-Based Classifiers in Colon Cancer Patients.
van de Weerd S; Smit MA; Roelands J; Mesker WE; Bedognetti D; Kuppen PJK; Putter H; Tollenaar RAEM; Roodhart JML; Hendrickx W; Medema JP; van Krieken JHJM
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293565
[TBL] [Abstract][Full Text] [Related]
9. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
Zhang S; Yang Y; Weng W; Guo B; Cai G; Ma Y; Cai S
J Exp Clin Cancer Res; 2019 Jan; 38(1):14. PubMed ID: 30630498
[TBL] [Abstract][Full Text] [Related]
10.
Hu L; Liu Y; Kong X; Wu R; Peng Q; Zhang Y; Zhou L; Duan L
Front Immunol; 2021; 12():658681. PubMed ID: 34093546
[No Abstract] [Full Text] [Related]
11. Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).
Ubink I; Bloemendal HJ; Elias SG; Brink MA; Schwartz MP; Holierhoek YCW; Verheijen PM; Boerman AW; Mathijssen RHJ; de Leng WWJ; de Weger RA; van Grevenstein WMU; Koopman M; Lolkema MP; Kranenburg O; Borel Rinkes IHM
BMC Cancer; 2017 Apr; 17(1):282. PubMed ID: 28424071
[TBL] [Abstract][Full Text] [Related]
12.
Chen S; Su T; Zhang Y; Lee A; He J; Ge Q; Wang L; Si J; Zhuo W; Wang L
Gut Microbes; 2020 May; 11(3):511-525. PubMed ID: 31910722
[TBL] [Abstract][Full Text] [Related]
13. Consensus molecular subtype classification of colorectal adenomas.
Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
[TBL] [Abstract][Full Text] [Related]
14. Enrichment of oral-derived bacteria in inflamed colorectal tumors and distinct associations of Fusobacterium in the mesenchymal subtype.
Younginger BS; Mayba O; Reeder J; Nagarkar DR; Modrusan Z; Albert ML; Byrd AL
Cell Rep Med; 2023 Feb; 4(2):100920. PubMed ID: 36706753
[TBL] [Abstract][Full Text] [Related]
15.
Kim HS; Kim CG; Kim WK; Kim KA; Yoo J; Min BS; Paik S; Shin SJ; Lee H; Lee K; Kim H; Shin EC; Kim TM; Ahn JB
Front Cell Infect Microbiol; 2023; 13():1101291. PubMed ID: 36960042
[TBL] [Abstract][Full Text] [Related]
16. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21.
Yang Y; Weng W; Peng J; Hong L; Yang L; Toiyama Y; Gao R; Liu M; Yin M; Pan C; Li H; Guo B; Zhu Q; Wei Q; Moyer MP; Wang P; Cai S; Goel A; Qin H; Ma Y
Gastroenterology; 2017 Mar; 152(4):851-866.e24. PubMed ID: 27876571
[TBL] [Abstract][Full Text] [Related]
17. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases.
Ubink I; van Eden WJ; Snaebjornsson P; Kok NFM; van Kuik J; van Grevenstein WMU; Laclé MM; Sanders J; Fijneman RJA; Elias SG; Borel Rinkes IHM; Aalbers AGJ; Kranenburg O
Br J Surg; 2018 Jan; 105(2):e204-e211. PubMed ID: 29341165
[TBL] [Abstract][Full Text] [Related]
18. Association of Fusobacterium nucleatum infection with the clinicopathological characteristics in colorectal cancer patients.
Pang SW; Armon S; Chook JB; Chew J; Peh KB; Lim WW; Peh SC; Teow SY
Mol Biol Rep; 2024 Jan; 51(1):124. PubMed ID: 38227097
[TBL] [Abstract][Full Text] [Related]
19. Parvimonas micra is associated with tumour immune profiles in molecular subtypes of colorectal cancer.
Löwenmark T; Li X; Löfgren-Burström A; Zingmark C; Ling A; Kellgren TG; Larsson P; Ljuslinder I; Wai SN; Edin S; Palmqvist R
Cancer Immunol Immunother; 2022 Oct; 71(10):2565-2575. PubMed ID: 35301576
[TBL] [Abstract][Full Text] [Related]
20.
Kong C; Yan X; Zhu Y; Zhu H; Luo Y; Liu P; Ferrandon S; Kalady MF; Gao R; He J; Yin F; Qu X; Zheng J; Gao Y; Wei Q; Ma Y; Liu JY; Qin H
Cancer Res; 2021 Sep; 81(17):4485-4498. PubMed ID: 34162680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
